Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP031: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension studyECCO '17 Barcelona
Year: 2017
Authors:

Panés J.*1, D'Haens G.R.2, Higgins P.D.R.3, Mele L.4, Moscariello M.4, Chan G.4, Wang W.4, Niezychowski W.4, Su C.4, Maller E.4

1Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain 2Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands 3University of Michigan, Ann Arbor, MI, United States 4Pfizer Inc, Collegeville, PA, United States

OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Sands B.E.2, Danese S.3, D'Haens G.R.4, Vermeire S.5, Schreiber S.6, Feagan B.7, Reinisch W.8,9, Friedman G.10, Woodworth D.10, Zhang H.10, Lawendy N.10, Niezychowski W.10, Su C.10, Panés J.*11

1Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States 2Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States 3IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy 4Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands 5Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 6Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany 7Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, ON, Canada 8McMaster University, Hamilton, ON, Canada 9Medical University of Vienna, Vienna, Austria 10Pfizer Inc, Collegeville, PA, United States 11Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

OP033: Reduction of tissue pSTAT3 in Crohn's disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitorECCO '17 Barcelona
Year: 2017
Authors:

Vermeire S.*1, De Hertogh G.2, Chen G.3, French D.4, Huntzicker E.4, Van der Aa A.5, Van Kaem T.5, Harrison P.5, Tasset C.5, Galien R.6, Pan Y.4, Feagan B.7, Sandborn W.8

1University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium 2University Hospitals Leuven, Department of Pathology, Leuven, Belgium 3Gilead Sciences, Department of Biostatistics, Foster City, United States 4Gilead Sciences, Biomarker Sciences, Foster City, United States 5Galapagos NV, Mechelen, Belgium 6Galapagos SASU, Romainville, France 7Robarts Resaerch Institute, Ontario, Canada 8University of California, Division of Gastroenterology, San Diego, United States

OP034: Efficacy and safety of abrilumab in subjects with moderate to severe ulcerative colitis: results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled studyECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Cyrille M.2, Hansen M.B.3, Feagan B.G.4, Loftus Jr. E.V.5, Rogler G.6, Vermeire S.7, Cruz M.L.2, Yang J.2, Sullivan B.A.2, Reinisch W.*8

1University of California San Diego, Department of Gastroenterology, La Jolla, United States 2Amgen, Thousand Oaks, United States 3University of Copenhagen, Copenhagen, Denmark 4Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States 6Universitätsspital Zürich, Zürich, Switzerland 7University Hospital Gasthuisberg, Leuven, Netherlands 8Medical University of Vienna, Vienna, Austria

OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Cyrille M.2, Berner Hansen M.3, Feagan B.G.4, Loftus Jr. E.V.5, Vermeire S.6, Cruz M.L.2, Mo M.2, Sullivan B.A.2, Reinisch W.*7

1University of California San Diego, La Jolla, United States 2Amgen Inc., Thousand Oaks, United States 3University of Copenhagen, Copenhagen, Denmark 4Robarts Research Institute, University of Western Ontario, London, Canada 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States 6University Hospitals Leuven, Leuven, Belgium 7Medical University Vienna, Vienna, Austria

OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Costello S.*1,2,3, Waters O.4, Bryant R.2,3, Katsikeros R.3, Makanyanga J.4, Schoeman M.2,3, Mountifield R.5, Tee D.6, Howell S.2, Hughes P.2, Conlon M.7, Roberts-Thomson I.1,2, Andrews J.2,3

1The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia 2University of Adelaide, School of Medicine, Adelaide, Australia 3The Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia 4Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia 5Flinders Medical Centre, Gastroenterology, Bedford Park, Australia 6Lyell McEwin Hospital, Gastroenterology, Elizabeth Vale, Australia 7CSIRO, Health and Biosecurity, Adelaide, Australia

OP037: Infants born to mothers with inflammatory bowel disease exhibit distinct microbiome features that persist up to 3 months of lifeECCO '17 Barcelona
Year: 2017
Authors:

Torres J.*1, Hu J.2, Eisele C.2, Nair N.2, Panchal H.2, Bao X.2, Niu X.2, Côté-Daigneault J.1, Jharap B.1, Maser E.1, Kornbluth A.1, Legnani P.1, George J.1, Dubinsky M.3, Stone J.4, Chen C.-L.4, Clemente J.2,5, Colombel J.-F.1, Peter I.2

1Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States 2Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York, United States 3Icahn School of Medicine at Mount Sinai, Department of Pediatrics, New York, United States 4Icahn School of Medicine at Mount Sinai, Obstetrics, Gynecology and Reproductive Science, New York, United States 5Icahn School of Medicine at Mount Sinai, Immunology, New York, United States

OP038: Impact of ileocecal resection in Crohn's disease patients on mucosal microbiotaECCO '17 Barcelona
Year: 2017
Authors:

Machiels K.*1, Pozuelo del Río M.2, Sabino J.1, Santiago A.2, Campos D.2, Wolthuis A.3, De Buck van Overstraeten A.3, D'Hoore A.3, Van Assche G.1, Ferrante M.1, Rutgeerts P.1, De Hertogh G.3, Vermeire S.1, Manichanh C.2

1University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium 2Vall d'Hebron Research Institute, Barcelona, Spain 3University Hospitals Leuven, KU Leuven, Leuven, Belgium

P001: The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBDECCO '17 Barcelona
Year: 2017
Authors:

Cheng X., Taranath R., Mattheakis L., Bhandari A., Liu D.

Protagonist Therapeutics, Milpitase, United States

P002: Inhibition of Axl signaling by BGB324 reduces fibrogenesis in human intestinal cells and human intestinal organoidsECCO '17 Barcelona
Year: 2017
Authors:

Steiner C.1, Rodansky E.2, Johnson L.A.2, Huang S.2, Spence J.1, Higgins P.D.*3

1University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, United States 2University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, Michigan, United States 3University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, MI, United States

P004: Stimulation of CYP450-mediated ω-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Ungaro F.*1,2, Tacconi C.3, Correale C.4, Massimino L.5, Corsetto P.6, Piontini A.2,4, Fonteyne P.7, Calcaterra F.8, Della Bella S.8, Spinelli A.8, Carvello M.8, Rizzo A.6, Vetrano S.2,4, Fiorino G.4,8, Furfaro F.4,8, Maddipati K.R.9, D'Alessio S.4,10, Danese S.2,4

1Humanitas Research Institute, Laboratory of Immunology in Gastroenterology, Rozzano, Italy 2Humanitas University, Rozzano, Italy 3Swiss Federal Institute of Technology, Zurich, Switzerland 4Humanitas Research Institute, Laboratory of Immunology in Gastroenterology, Milan, Italy 5University of Milan, School of Medicine and Surgery, Milan, Italy 6University of Milan, Department of Pharmacology and Biomolecular Science, Milan, Italy 7San Raffaele Research Institute, Milano, Italy 8Humanitas Research Institute, Rozzano, Italy 9Wayne State University, Department of Pathology, Detroit, United States 10University of Milan, Department of Biotechnology and Translational Medicine, Milan, Italy

P005: Establishing a porcine model to translate anorectal stem cell organoid models to elucidate the aetiology of perianal Crohn's fistulaeECCO '17 Barcelona
Year: 2017
Authors:

Adegbola S.*1, Moore J.2, Sahnan K.1, Tozer P.1, Phillips R.1, Warusavitarne J.3, Faiz O.1, Hart A.4

1St Mark's Academic Institute, Surgery, London, United Kingdom 2Curileum Discovery Ltd, Northwick Park Institute of Medical Research/St Mark's Hospital Site, London, United Kingdom 3St Mark's Hospital, London, London, United Kingdom 4St Mark's Academic Institute, Gastroenterology, London, United Kingdom

P006: Transcriptomic profiling of intestinal macrophages isolated from patients reveals a profound gene expression reprogramming underlying IBD pathogenesisECCO '17 Barcelona
Year: 2017
Authors:

Dharmasiri S.*1,2, Garrido Martin E.M.2, Sanchez-Elsner T.2, Cummings J.R.F.1

1Southampton General Hospital, Department of Gastroenterology, Southampton, United Kingdom 2University of Southampton, Department of Clinical and Experimental Sciences, Southampton, United Kingdom

P007: Oral tyrosine kinase 2 inhibitor ameliorates T cell transfer colitisECCO '17 Barcelona
Year: 2017
Authors:

De Vries L.*1,2, Wildenberg M.1,2, van Hamersveld P.2, Welting O.2, Verseijden C.2, D'Haens G.1, De Jonge W.2

1Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands 2Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands

P008: Common and different inflammatory features in inflammatory bowel disease and colon cancerECCO '17 Barcelona
Year: 2017
Authors:

Lo Presti E.*1, Di Mitri R.2, Dieli F.1, Mocciaro F.2, Cilluffo M.G.3, Pecoraro G.M.4, Russo G.2, Meraviglia S.1

1University of Palermo, Department of Biopathology and Medical Biotechnologies (DIBIMED), University of Palermo; (CLADIBIOR), Palermo, Italy 2ARNAS Civico-Di Cristina-Benfratelli Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy 3A.O.U. Policlinico “G. Giaccone”, Gastroenterology and Hepatology Unit, Palermo, Italy 4Cattinara Hospital, Department of Gastroenterolgy, Trieste, Italy

P009: Autophagy stimulation reduces mucosal NF-κB protein levels and ameliorates murine colitisECCO '17 Barcelona
Year: 2017
Authors:

Macias Ceja D.C.*1,2, Cosín-Roger J.3, Ortiz-Masià D.2, Salvador P.2, Gisbert-Ferrándiz L.2, Hernandez C.1,3, Esplugues J.V.1,2,3, Calatayud S.2,3, Barrachina M.D.2,3

1Fisabio Hospital Peset, Valencia, Spain 2University of Valencia, Valencia, Spain 3CIBERehd, Valencia, Spain

P010: Effects of cigarette smoke on the DSS-induced colitis model in C57Bl/6 miceECCO '17 Barcelona
Year: 2017
Authors:

Phillips B.1, Lo Sasso G.*2, Talikka M.2, Veljkovic E.1, Martin F.2, Elamin A.2, Guedj E.2, Ivanov N.2, Peitsch M.2, Hoeng J.2

1Philip Morris International Research Laboratories, Department of Reduced-Risk Products, Singapore, Singapore 2Philip Morris International R&D, Department of Reduced-Risk Products, Neuchatel, Switzerland

P011: Evaluation the intestinal barrier function patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Abdulganieva D.*1, Mukhametova D.1, Koshkin S.2, Zinkevich O.3, Saphina N.3, Abdulkhakov S.1,2, Odintsova A.4, Koporulina M.3

1Kazan State Medical University, Kazan, Russian Federation 2Kazan (Volga region) Federal University, Kazan, Russian Federation 3Kazan State Medical Academy, Kazan, Russian Federation 4Republican Clinical Hospital, Kazan, Russian Federation

P012: Ral activation exacerbates colonic inflammation through the impairment of intestinal barrier function in experimental murine colitisECCO '17 Barcelona
Year: 2017
Authors:

Minami N.*1, Matsuura M.1, Yamamoto S.1, Honzawa Y.1, Yamada S.1, Koshikawa Y.1, Okabe M.1, Seno H.1, Horiuchi H.2, Nakase H.3

1Graduate School of Medicine, Kyoto University, Gastroenterology and Hepatology, Kyoto, Japan 2Institute of Development, Aging and Cancer, Tohoku University, Molecular and Cellular Biology, Sendai, Japan 3Sapporo Medical University School of Medicine, Gastroenterology and Hepatology, Sapporo, Japan

P013: Decreased fibrogenesis in CH25H knockout mice in a mouse model of intestinal fibrosisECCO '17 Barcelona
Year: 2017
Authors:

Raselli T., Wyss A., Gonzalez Alvarado M.N., Mamie C., Rogler G., Hausmann M., Misselwitz B.

University of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland